89Bio Inc

NASDAQ:ETNBUnited States

89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.

Contact Information

Headquarters

142 Sansome Street, Second FloorSan Francisco, CA, United States 94104

Phone

415-432-9270

Fax

302-655-5049

Executives

Independent Chairman of the Board of Director

Steven Altschuler

Chief Executive Officer, Director

Rohan Palekar

Chief Financial Officer

Ryan Martins

Chief Technical Operations Officer and Head of Quality

Quoc Le-Nguyen

Chief Medical Officer

Hank Mansbach